Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Nat Clin Pract Oncol. 2008 Aug;5(8):487-91. doi: 10.1038/ncponc1157. Epub 2008 Jun 17.

    Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.

    Source

    Department of Neurology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA. splotkin@partners.org

    Abstract

    BACKGROUND:

    A 48-year-old man presented to a neurologist with complaints of bilateral hearing loss and tinnitus. The patient was a member of a large family affected by neurofibromatosis type 2 and first noted hearing loss 10 years before presentation.

    INVESTIGATIONS:

    Medical and neurological examination, MRI scan of the brain and spinal cord, pure-tone audiometry, NU-6 monosyllabic word test with phoneme scoring, City University of New York topic-related sentences test, noise/voice test of minimal auditory capability battery.

    DIAGNOSIS:

    Progressive neurofibromatosis-type-2-related vestibular schwannomas.

    MANAGEMENT:

    Annual cranial MRI and audiology, surgical resection of right vestibular schwannoma, high-power behind-the-ear hearing aid, erlotinib therapy for progressive left vestibular schwannoma.

    PMID:
    18560388
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Nature Publishing Group

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk